Summary of the included studies focused on HRQOL in patients with thalassemia following HSCT
| Author, y . | Country . | Age . | Participants . | Specific diagnosis . | Study type (time from HSCT) . | QOL tool . | Conditioning regimen . | GRADE . |
|---|---|---|---|---|---|---|---|---|
| Caocci et al,45 2006 | Italy | Median: 24 Range: 17-37 | Patient: 19 | Not reported | Cross-Sectional (≥ 300 d post-HSCT) | EORTC QLQ-C30 | Myeloablative | Moderate |
| Caocci et al,44 2011 | Italy | Median: 10 Range: 5-17 | Patient: 28 Parent: 28 | β-thalassemia major | Longitudinal (1-mo pre-HSCT, then 3, 6, and 18 mo post-HSCT) | PedsQL 4.0 GCS | Myeloablative | Moderate |
| Caocci et al,46 2016 | Italy | Mean: 33 Median: 21 Range: 12-29 | Patient: 71 Control: 71 | Not reported | Cross-Sectional (median 21 y post-HSCT, range 12-29) | SF-36 | Not reported | Moderate |
| Cheuk et al,47 2008 | Hong Kong | Median: 15.2 Range: 5.3-30.4 | Patients: 24 Control: 74 | β-Thalassemia major, hemoglobin Bart's disease | Cross-Sectional (median 6.5 y post-HSCT, range 1.1-13.5) | WHOQoL-BREF(HK) and PedsQL | Not reported | Moderate |
| Javanbakht et al,48 2015 | Iran | Mean: 20 Range: 5-35 | Patients: 44 Control: 152 | Not reported | Cross-sectional (not reported) | EQ-5D-3L, EQ-VAS, SF-36 | Not reported | Moderate |
| Kelly et al,53 2012 | USA | Median: 8 Range: 5-18 | Patients: 6 Parents: 6 Control: 268 | Not reported | Longitudinal (pre-HSCT, then 1.5, 3, 6, and 12 mo post-HSCT) | CHRIs | Myeloablative regimen mostly | Moderate |
| Kisecik Sengul et al,49 2017 | Turkey | Mean: 10.68 Range: 2-18 | Parent: 26 | Not reported | Cross-sectional (not reported) | PedsQoL | Chemotherapy and chemoradiotherapy | Moderate |
| La Nasa et al,50 2013 | Italy | Median: 34 Range: 21-48 | Patient: 109 Control: 124 | β-thalassemia major | Cross-Sectional (not reported) | SF-36, FACT-BMT | Myeloablative (busulfan, and cyclophosphamide) | Moderate |
| Patel et al,51 2018 | India | Median 10 Range: 5-18 | Patients and parents: 40 Control: 60 | Thalassemia major | Cross-Sectional (median 5 y post-HSCT, range 2-10) | PedsQL 4.0 GCS | Myeloablative (fludarabine, thiotepa, treosulfan, and antithymocyte globulin) | Low |
| Uygun et al,52 2012 | Turkey | Median 11.6 Range: 3.5-25.7 | Patients: 45 Parents: 40 Control: 50 | Thalassemia major | Cross-sectional (not reported) | PedsQL 4.0, WHOQoL-BREF | Myeloablative | Moderate |
| Author, y . | Country . | Age . | Participants . | Specific diagnosis . | Study type (time from HSCT) . | QOL tool . | Conditioning regimen . | GRADE . |
|---|---|---|---|---|---|---|---|---|
| Caocci et al,45 2006 | Italy | Median: 24 Range: 17-37 | Patient: 19 | Not reported | Cross-Sectional (≥ 300 d post-HSCT) | EORTC QLQ-C30 | Myeloablative | Moderate |
| Caocci et al,44 2011 | Italy | Median: 10 Range: 5-17 | Patient: 28 Parent: 28 | β-thalassemia major | Longitudinal (1-mo pre-HSCT, then 3, 6, and 18 mo post-HSCT) | PedsQL 4.0 GCS | Myeloablative | Moderate |
| Caocci et al,46 2016 | Italy | Mean: 33 Median: 21 Range: 12-29 | Patient: 71 Control: 71 | Not reported | Cross-Sectional (median 21 y post-HSCT, range 12-29) | SF-36 | Not reported | Moderate |
| Cheuk et al,47 2008 | Hong Kong | Median: 15.2 Range: 5.3-30.4 | Patients: 24 Control: 74 | β-Thalassemia major, hemoglobin Bart's disease | Cross-Sectional (median 6.5 y post-HSCT, range 1.1-13.5) | WHOQoL-BREF(HK) and PedsQL | Not reported | Moderate |
| Javanbakht et al,48 2015 | Iran | Mean: 20 Range: 5-35 | Patients: 44 Control: 152 | Not reported | Cross-sectional (not reported) | EQ-5D-3L, EQ-VAS, SF-36 | Not reported | Moderate |
| Kelly et al,53 2012 | USA | Median: 8 Range: 5-18 | Patients: 6 Parents: 6 Control: 268 | Not reported | Longitudinal (pre-HSCT, then 1.5, 3, 6, and 12 mo post-HSCT) | CHRIs | Myeloablative regimen mostly | Moderate |
| Kisecik Sengul et al,49 2017 | Turkey | Mean: 10.68 Range: 2-18 | Parent: 26 | Not reported | Cross-sectional (not reported) | PedsQoL | Chemotherapy and chemoradiotherapy | Moderate |
| La Nasa et al,50 2013 | Italy | Median: 34 Range: 21-48 | Patient: 109 Control: 124 | β-thalassemia major | Cross-Sectional (not reported) | SF-36, FACT-BMT | Myeloablative (busulfan, and cyclophosphamide) | Moderate |
| Patel et al,51 2018 | India | Median 10 Range: 5-18 | Patients and parents: 40 Control: 60 | Thalassemia major | Cross-Sectional (median 5 y post-HSCT, range 2-10) | PedsQL 4.0 GCS | Myeloablative (fludarabine, thiotepa, treosulfan, and antithymocyte globulin) | Low |
| Uygun et al,52 2012 | Turkey | Median 11.6 Range: 3.5-25.7 | Patients: 45 Parents: 40 Control: 50 | Thalassemia major | Cross-sectional (not reported) | PedsQL 4.0, WHOQoL-BREF | Myeloablative | Moderate |
CHRIs, Child Health Rating Inventory; EORTC QLQ-C30, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire 30-Items; EQ-5D-3L, EuroQol 5 dimensions 3-level; EQ-VAS, EuroQol visual analog scale; FACT-BMT, Functional Assessment of Cancer Therapy-Bone Marrow Transplant; WHOQoL-BREF, World Health Organization Quality of Life Instruments.